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Diabetes mellitus is a common endocrine disease in cats. It is currently assumed that 
approximately 80% of diabetic cats suffer from a type 2 like diabetes, which is a 
heterogeneous disease due to a combination of insulin resistance and -cell failure. 
Risk factors are obesity, increasing age, male gender, being neutered, physical 
inactivity, glucocorticoid and progestin administration, and being a Burmese cat (at 
least in some countries). Other specific types of diabetes (formerly called secondary 
diabetes) account for approximately 20% of cases and include pancreatitis, 
hyperadrenocorticism, hypersomatotropism and the application of progestins or 
glucocorticoids.  
Diabetes typically occurs in middle-aged to old cats, with a strong sex predilection for 
males. Approximately 60% of diabetic cats are overweight, 35 are normalweight and 
5% underweight (1). Most diabetic cats have the classical symptoms of diabetes, 
namely polyuria, polydipsia, polyphagia and weight loss. About 10% have overt 
symptoms of diabetic neuropathy, manifested as hind limb weakness, decreased 
ability to jump and plantigrade posture. Cats are prone to stress hyperglycemia which 
has to be differentiated from hyperglycemia due to diabetes by repeated blood 
glucose measurements or by measurement of fructosamine. Further work-up should 
clarify the severity of diabetes, presence of concurrent disease and presence of 
underlying disease/factors. Treatment should be initiated immediately and include 
twice daily insulin application (intermediate acting insulin) and high-protein-low 
carbohydrate diet (therapy will be covered in more detail in the presentation on 
“Diabetic remission”).  
The general aim of therapy is to provide a good quality of life by eliminating clinical 
signs of diabetes and preventing complications such as hypoglycemia and 
ketoacidosis. Immediate therapy may reverse the effects of glucose toxicity and the 
diabetes may go into remission. Initially, frequent re-evaluations should be 
scheduled, with time, intervals can be extended. In our hospital re-evaluations are 
suggested 1, 3, 8, 12 weeks after diagnosis and then approximately every 4 months.  
The owner should assess his animal with regard to the clinical signs of diabetes 
mellitus on a daily basis. Body weight should be taken at least once a week. It is 
important that the owner is familiar with the clinical signs of the most important 
complications of diabetes mellitus, i.e. hypoglycemia and diabetic ketoacidosis. In 
general, single measurements are considered insufficient to assess metabolic 
control. Blood glucose curves (BGCs) are necessary to evaluate insulin efficacy, 
glucose nadir, duration of insulin effect, degree of fluctuation and the Somogyi effect. 
We prefer that owners give insulin and food at home, and then bring the animal 
quickly to the hospital (within 2 hours) for a BGC. This approach eliminates the effect 
of lack of food intake on blood glucose levels, at least in animals which are only fed 
at the time of insulin administration.  
However, the procedure is time-consuming and expensive and therefore in many 
patients may not be carried out as often as indicated and the concentration of blood 
glucose can be markedly influenced by the stress of hospitalisation. We therefore 
recommend to the owners of diabetic cats to perform so-called home-monitoring 
(HM) of capillary blood glucose and approximately 70% of the owners are willing and 
able to do this. Usually, we introduce HM 3 weeks after the initial presentation.  
Capillary blood is obtained from the pinna or paw and glucose is determined with a 
portable glucometer (PBGM). Owners can certainly be taught to interpret a BGC; 
however, we prefer that decisions regarding changes in the insulin dose be made by 
the veterinarian and therefore, BGCs be sent to the hospital. Ideally, the glucose 
concentration ranges from 12 – 15 mmol/l before the insulin injection with a nadir 
from 5 – 9 mmol/l. A low nadir may occur in insulin overdose (including sudden 
improvement of insulin-resistant states), excessive overlap of insulin actions and lack 
of food intake. If the nadir is > 9 mmol/l, insulin underdose, the counter-regulatory 
phase of the Somogyi effect and technical problems involving the injection of insulin 
by the owner must be considered. In diabetic pets that already receive high doses of 
insulin (> 1.5 U/kg/injection), concurrent diseases causing insulin resistance are also 
possible. The duration of effect is defined as the time from insulin injection through 
the glucose nadir until the blood glucose concentration exceeds 12 – 15 mmol/l. If the 
duration is less than 8 – 10 hours, the animal usually has signs of diabetes, and if the 
duration is longer than 14 hours and the insulin is given twice daily, the risk of 
hypoglycemia increases. In humans, it is well known that blood glucose 
concentrations can vary markedly from day to day. There is also a high degree of 
variability among BGCs of diabetic pets. One of the major advantages of HM is that it 
enables frequent generation of BGCs, which may be of particular importance in 
animals that are difficult to regulate. In those cases, more than one BGC can be 
generated at home before a change in treatment is initiated. HM has replaced 
measurement of urine glucose nearly completely in our hospital.  
We routinely measure the fructosamine concentration during the re-evaluations. It 
increases when glycemic control worsens and decreases when glycemic control 
improves. Since even well-controlled pets may be slightly to moderately 
hyperglycemic throughout the day, fructosamine concentrations will not usually 
decrease into the normal range. On the contrary, a normal fructosamine 
concentration should raise concern about prolonged periods of hypoglycemia (insulin 
overdose, diabetic remission). Metabolic control is usually good when fructosamine 
levels are between 350 and 450 μmol/l, moderate when values are between 450 and 
550 μmol/l and poor when levels are > 550 – 600 μmol/l (2).  
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